ID   FM93/2
AC   CVCL_C617
SY   FM-93/2
DR   cancercelllines; CVCL_C617
DR   Cosmic; 2163783
DR   ECACC; 13012419
DR   ESTDAB; ESTDAB-033
DR   Wikidata; Q54835076
RX   PubMed=15592718;
RX   PubMed=27600516;
RX   PubMed=23851445;
CC   HLA typing: A*02:01,26:01; B*40:01,44:02; C*03:04,05:01; DPB1*04:02,03:01:01; DQB1*03:01:01,05:01; DRB1*14:01:01,04:01:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.795_796GG>AA); Zygosity=Unspecified (PubMed=23851445).
CC   Omics: HLA class I peptidome analysis by proteomics.
ST   Source(s): ECACC=13012419; ESTDAB=ESTDAB-033
ST   Amelogenin: X
ST   CSF1PO: 12,14
ST   D13S317: 11
ST   D16S539: 11,12
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 9
ST   FGA: 20
ST   TH01: 9,9.3
ST   TPOX: 9
ST   vWA: 17 (ESTDAB=ESTDAB-033)
ST   vWA: 17,18 (ECACC=13012419)
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9680 ! FM93
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 17
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=27600516; DOI=10.1007/s00262-016-1897-3; PMCID=PMC5509013;
RA   Gloger A., Ritz D., Fugmann T., Neri D.;
RT   "Mass spectrometric analysis of the HLA class I peptidome of melanoma
RT   cell lines as a promising tool for the identification of putative
RT   tumor-associated HLA epitopes.";
RL   Cancer Immunol. Immunother. 65:1377-1393(2016).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//